{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:56:59Z","timestamp":1789394219563,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"am","delay-in-days":395,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.therap.2023.07.007","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T16:46:05Z","timestamp":1690476365000},"page":"371-378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Drug-related hypophosphatemia: Descriptive study and case\/non-case analysis of the French national pharmacovigilance database"],"prefix":"10.1016","volume":"79","author":[{"given":"Eve-Marie","family":"Thillard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Sade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle","family":"Michot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Bres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie-Pierre","family":"Jonville-Bera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2023.07.007_bib0160","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.amjmed.2005.02.014","article-title":"Hypophosphatemia: an update on its etiology and treatment","volume":"118","author":"Gaasbeek","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.therap.2023.07.007_bib0165","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40264-019-00888-1","article-title":"Drug-induced hypophosphatemia: current insights","volume":"43","author":"Megapanou","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2023.07.007_bib0170","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/qjmed\/hcq039","article-title":"Medication-induced hypophosphatemia: a review","volume":"103","author":"Liamis","year":"2010","journal-title":"QJM"},{"key":"10.1016\/j.therap.2023.07.007_bib0175","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.lpm.2017.09.002","article-title":"Causes, cons\u00e9quences et traitement de l\u2019hypophosphor\u00e9mie\u00a0: une revue syst\u00e9matique de la litt\u00e9rature","volume":"46","author":"Padelli","year":"2017","journal-title":"Presse Med"},{"key":"10.1016\/j.therap.2023.07.007_bib0180","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jbspin.2006.09.002","article-title":"Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods","volume":"73","author":"Montastruc","year":"2006","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.therap.2023.07.007_bib0185","first-page":"111","article-title":"Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France","volume":"40","author":"B\u00e9gaud","year":"1985","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.07.007_bib0190","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2515\/therapie\/2013016","article-title":"Updating the French method for the causality assessment of adverse drug reactions","volume":"68","author":"Arimone","year":"2013","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.07.007_bib0195","unstructured":"EMA. Serious adverse reaction [Internet]. European Medicines Agency. 2023. https:\/\/www.ema.europa.eu\/en\/glossary\/serious-adverse-reaction. [Accessed 21 August 2023]."},{"key":"10.1016\/j.therap.2023.07.007_bib0200","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case \u2013 non-case studies: principle, methods, bias and interpretation","volume":"74","author":"Faillie","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.07.007_bib0205","unstructured":"vih.org. Les chiffres du VIH en France. 2014. https:\/\/vih.org\/dossier\/les-chiffres-du-vih-en-france\/. [Accessed 21 August 2023]."},{"key":"10.1016\/j.therap.2023.07.007_bib0210","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.pcl.2018.09.002","article-title":"Fanconi Syndrome","volume":"66","author":"Foreman","year":"2019","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.therap.2023.07.007_bib0215","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/ki.2010.318","article-title":"Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities","volume":"78","author":"Herlitz","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.therap.2023.07.007_bib0220","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.amjmed.2004.03.025","article-title":"Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure","volume":"117","author":"Rifkin","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.therap.2023.07.007_bib0225","first-page":"184","article-title":"Is tenofovir alafenamide safer than tenofovir disoproxil fumarate for the kidneys?","volume":"18","author":"Aloy","year":"2016","journal-title":"AIDS Rev"},{"key":"10.1016\/j.therap.2023.07.007_bib0230","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s10067-014-2627-x","article-title":"Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients","volume":"35","author":"Mateo","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.therap.2023.07.007_bib0235","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1086\/430257","article-title":"Guidelines for the Management of Chronic Kidney Disease in HIV-Infected Patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America","volume":"40","author":"Gupta","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.therap.2023.07.007_bib0240","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. 2023. https:\/\/base-donnees-publique.medicaments.gouv.fr\/. [Accessed 21 August 2023]."},{"key":"10.1016\/j.therap.2023.07.007_bib0245","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bpobgyn.2016.09.007","article-title":"Iron deficiency and iron deficiency anaemia in women","volume":"40","author":"Percy","year":"2017","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.therap.2023.07.007_bib0250","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF01496662","article-title":"Hypophosphatemia induced by intravenous administration of saccharated iron oxide","volume":"61","author":"Okada","year":"1983","journal-title":"Klin Wochenschr"},{"key":"10.1016\/j.therap.2023.07.007_bib0255","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1210\/jc.2008-2396","article-title":"FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study","volume":"94","author":"Schouten","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.therap.2023.07.007_bib0260","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S8756-3282(97)00084-7","article-title":"Saccharated ferric oxide (SFO)-induced osteomalacia: in vitro inhibition by SFO of bone formation and 1,25-dihydroxy-vitamin D production in renal tubules","volume":"21","author":"Sato","year":"1997","journal-title":"Bone"},{"key":"10.1016\/j.therap.2023.07.007_bib0265","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.therap.2021.04.008","article-title":"Hypophosphat\u00e9mie et fer injectable\u00a0: \u00e0 propos d\u2019un cas et revue de la litt\u00e9rature","volume":"76","author":"Lecoq","year":"2021","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.07.007_bib0270","doi-asserted-by":"crossref","first-page":"e124486","DOI":"10.1172\/jci.insight.124486","article-title":"Randomized trial of intravenous iron-induced hypophosphatemia","volume":"3","author":"Wolf","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.therap.2023.07.007_bib0275","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/gutjnl-2022-327897","article-title":"Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial","volume":"72","author":"Zoller","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.therap.2023.07.007_bib0280","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/ckj\/sfab078","article-title":"Hypophosphatemia in cancer patients","volume":"14","author":"Adhikari","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.therap.2023.07.007_bib0285","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s00520-014-2521-8","article-title":"Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency","volume":"23","author":"Watkins","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.therap.2023.07.007_bib0290","doi-asserted-by":"crossref","DOI":"10.21767\/2471-8041.100059","article-title":"Profound and protracted hypophosphatemia after a single dose of zoledronic acid infusion for osteoporosis associated with normocalcemic primary hyperparathyroidism","volume":"03","author":"Chiam","year":"2017","journal-title":"Med Case Rep"},{"key":"10.1016\/j.therap.2023.07.007_bib0295","first-page":"601","article-title":"Development of a practice standard for monitoring adult patients receiving bone-modifying agents at a community cancer center","volume":"9","author":"Nguyen","year":"2018","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.therap.2023.07.007_bib0300","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.therap.2022.03.001","article-title":"Pharmacovigilance and drug safety: fair prescribing and clinical research","volume":"77","author":"Montastruc","year":"2022","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.07.007_bib0305","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/jama.288.13.1588","article-title":"Rates of spontaneous reporting of adverse drug reactions in France","volume":"288","author":"B\u00e9gaud","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2023.07.007_bib0310","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.therap.2020.02.022","article-title":"Uses of pharmacovigilance databases: an overview","volume":"75","author":"Bihan","year":"2020","journal-title":"Therapie"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723001087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723001087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T05:39:38Z","timestamp":1717220378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595723001087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0040595723001087"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2023.07.007","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-related hypophosphatemia: Descriptive study and case\/non-case analysis of the French national pharmacovigilance database","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2023.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}